Akari Therapeutics, Plc (AKTX)
| Market Cap | 3.88M -90.5% |
| Revenue (ttm) | n/a |
| Net Income | -28.05M |
| EPS | -26.91 |
| Shares Out | 1.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,911 |
| Open | 3.730 |
| Previous Close | 3.740 |
| Day's Range | 3.430 - 3.950 |
| 52-Week Range | 3.015 - 56.800 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 26.78 (+680.76%) |
| Earnings Date | May 19, 2026 |
About AKTX
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AKTX stock is "Buy." The 12-month stock price target is $26.78, which is an increase of 680.76% from the latest price.
News
Akari Therapeutics, Quarterly report: Q1 2026
Akari Therapeutics, has published its Q1 2026 quarterly earnings report on May 19, 2026.
Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026
Akari Therapeutics secures European patent for Thailanstatin-based payloads
Akari Therapeutics (AKTX) announced the grant of a European patent that for its global intellectual property position. The newly granted patent, titled “Thailanstatin Analogs,” provides broad composit...
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC A...
Akari Therapeutics, Registration statement: Registration filing
Akari Therapeutics, filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
Akari Therapeutics receives Australian patent for core payload technology
Akari Therapeutics (AKTX) announced the acceptance of an Australian patent covering its core payload technology, and further expanding protection of its proprietary ADC platform. The accepted patent i...
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari's global intellectual property acr...
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:...
Akari Therapeutics announces presentation of preclinical data for AKTX-101
Akari Therapeutics (AKTX) announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research, AACR, Annual Meeting 2026...
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor r...
Akari Therapeutics downgraded to Hold from Buy at Maxim
Maxim downgraded Akari Therapeutics (AKTX) to Hold from Buy without a price target The selloff post the partnership with WuXi XDC is due in part due to Akari’s additional capital…
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
CEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implications for platform validation and development acceleration
Akari Therapeutics downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Akari Therapeutics (AKTX) to Hold from Buy.
Akari Therapeutics announces strategic partnership with WuXi XDC
Akari Therapeutics (AKTX) announced a strategic partnership with WuXi XDC to accelerate the development of Akari’s novel PH1 payload. Akari is working to advance its program, AKTX-101, into a Phase…
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026
Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Akari Therapeutics (AKTX) to $27 from $1.60 and keeps a Buy rating on the shares. The firm cites the new common shares…
Akari Therapeutics trading halted, news pending
19:50 EDT Akari Therapeutics (AKTX) trading halted, news pending
Akari Therapeutics, Annual report: Q4 2025
Akari Therapeutics, has published its Q4 2025 annual report on March 30, 2026.
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice mo...
Akari Therapeutics Announces ADS Ratio Change
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice mo...
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Highlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline
Akari Therapeutics appoints Gokhale to its Scientific Advisory Board
Akari Therapeutics (AKTX) announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to i...
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncolog...
Akari Therapeutics appoints Olga Anczukow to SAB
Akari Therapeutics (AKTX) announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board. She currently serves as an Associate Professor at The Jackson Laboratory for Genomic Medic...
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncolog...